
Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Researchers analyzed historical characteristics of bleeding disorders among women by highlighting clinical challenges and management strategies.

Investigators note that low itch and mild disease severity are maintained following a treatment-free interval of 80 days.

Researchers investigated the health benefits, utilization, harms, and costs associated with the use of alternative methods for colorectal cancer screening in Australia.

A conversation with Chelsee Jensen, PharmD, BCPS, director of formulary management at the Mayo Clinic.

COVID-19 vaccination before a SARS-CoV-2 infection was associated with a 75% reduced likelihood of long COVID symptoms that impact daily functioning among patients between the ages of 5 and 17 years.

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol levels could potentially be a valuable biomarker for determining the risk of diabetic kidney disease.

IQVIA released a report detailing pharmacists’ authority to administer vaccines in the US as well as adults’ overall vaccination rates by state.

In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.

The prevalence of depression and anxiety were also higher among younger patients and those who had a longer duration of pain.

Among postmenopausal women, researchers explored associations between intentional weight loss and waist circumference (WC) reduction and mortality.

The event will focus on clinical practice expansion for community pharmacies and how to make them a revenue-generating health care destination.

Coalition for Epidemic Preparedness Innovations experts warned of the potential for bird flu to become a pandemic event if officials don’t prepare quickly.

The ADjoin long-term extensive study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

Omalizumab-igec is approved to treat moderate to severe persistent asthma in patients 6 years and older whose symptoms are not well controlled with inhaled corticosteroids.

Investigators report that the safety profile is also similar between both drugs.

After adjusting for confounding factors, women who experienced premature menopause had an increased risk of T2D.

The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.

Clinical pharmacists were asked to provide interventions to improve their patients’ rate of not showing up to a pharmacy appointment.

Cebranopadol met its primary endpoint of reduction in pain intensity as measured by the Pain Numeric Rating Scale (NRS) area under the curve from 2 through 48 hours.

Researchers conducted a survey asking pharmacists their perspectives on addressing patients’ social determinants of health.

Currently, there is a gap in treatment for this patient population and intracerebral hemorrhagic stroke is considered an orphan disease.

The approval is the first significant innovation for the delivery of epinephrine for this population in more than 35 years, according to the company news release.

Researchers investigated the acceptability of community pharmacy-led influenza vaccination and patients’ willingness to return for future immunization.

The main motivations for preferring vaccination included previous experience with an RSV infection and desire to protect the baby.

Researchers analyzed the association between adherence to a Mediterranean diet and obesity cancers, with a focus on the mediating role adiposity plays throughout the process.

All dosages of semaglutide (Wegovy) under the new program will be available at $499 per month for patients that are uninsured or who do not have coverage for obesity medication.

Investigators found that zonisamide was associated with a reduction in monthly migraine days for pediatric populations.

In a third installment of our interview series with Chris Robinson, MD, PhD, we looked at the future of pain management and emerging technologies being used for treatment.

“The Commission reinforces that obesity is a disease and not due to lack of motivation, willpower, discipline, or laziness,” Robert F. Kushner said.